The outcomes of the ALPS study 1 published in the August 2020 issue of the JEVT are without doubt remarkable for a no-option chronic limb-threatening ischemia (CLTI) population. This retrospective multicenter study represents the largest population of patients (n=32) to date treated with percutaneous deep venous arterialization (pDVA) using the Limflow device (Limflow, Paris, France) with midterm results. The trial reports a 97% technical success rate, with limb salvage rates of 86.8%, 79.8%, and 79.8% at 6, 12, and 24 months, respectively, and corresponding complete wound healing rates of 36.6%, 68.2%, and 72.7%. These results are within the range for those previously reported by Mustapha et al 2 in the PROMISE I trial.Although scarcely mentioned by the authors, other approaches for proximal pDVA (PIPER), 3 distal pDVA, 4 and the venous arterialization simplified technique (VAST) 5,6 have also consistently achieved equivalent results both for limb salvage and wound healing. 7 These alternative maneuvers should not be dismissed because the majority of the physicians are currently performing their pDVA procedures using these techniques owing to the limited availability and increased cost of the Limflow device.Despite these encouraging results, the exact mechanism of action of pDVA remains unclear. It has been suggested that the use of the venous bed as a conduit for perfusion successfully increases flow through existing hibernating collaterals, improves tissue perfusion and nutrition in the capillary beds, and stimulates angiogenesis. 2 As a result, DVA improves microvascularization in target skeletal muscles and reduces ischemic markers, with a reduction in venous lactate. 8 Moreover, in the ALPS trial 1 (as in other studies), TcPO 2 , a reliable predictor of wound healing, rose to significant levels 6 to 8 weeks after DVA (45 days postprocedure).At this time there are also several practical aspects to pDVA that generate controversy and remain unsolved. Below are a few of these questions.